Congress trades
Neurocrine Biosciences, Inc. (NBIX)
About Neurocrine Biosciences, Inc.
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Kyle W. Gano
- Employees
- 2,500
- Listed since
- May 23, 1996
- Market value
- $15.6B
- Price to earnings
- 22.0
- Earnings per share
- $6.99
- Dividend yield
- -
Earnings
6 reported quarters · next on Oct 27, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Jul 30, 2026 | $1.39 | $1.65 | $959.0M | $891.2M | EPS missRevenue beat |
| Q1 FY2026reported May 5, 2026 | $1.94 | $1.22 | $814.5M | $768.3M | EPS beatRevenue beat |
| Q4 FY2025reported Feb 11, 2026 | $1.88 | $1.80 | $805.5M | $790.5M | EPS beatRevenue beat |
| Q3 FY2025reported Oct 28, 2025 | $2.04 | $1.58 | $794.9M | $806.8M | EPS beatRevenue in line |
| Q2 FY2025reported Jul 30, 2025 | $1.06 | $0.98 | $687.5M | $746.4M | EPS beatRevenue miss |
| Q1 FY2025reported May 5, 2025 | $0.08 | $0.54 | $572.6M | $559.6M | EPS missRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 15, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Matthew C. AbernethyChief Financial Officer | $920K | $5.8M | $6.8M | $13.4M |
| Sanjay Keswani, M.D.Chief Medical Officer Jude Onyia, Ph.D. Chief Scientif | $379K | $4.0M | $4.6M | $9.0M |
| Eiry W. Roberts, M.D. | $721K | $3.0M | $3.7M | $7.4M |
| Eric BenevichChief Commercial Officer | $726K | $2.5M | $3.1M | $6.3M |
The summary compensation table from the 2025 proxy statement, current executives only. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Blackrock, Inc. | $2.3B | 13,711,607 | +2.4% | 13.58% |
| Jpmorgan Chase & Co | $1.1B | 6,398,674 | +17.6% | 6.34% |
| Dodge & Cox | $941.2M | 5,584,707 | +2.3% | 5.53% |
| Vanguard Portfolio Management LLC | $838.3M | 4,974,083 | +5.2% | 4.92% |
| Vanguard Capital Management LLC | $766.0M | 4,545,339 | +0.7% | 4.50% |
| State Street Corp | $739.1M | 4,385,598 | +0.7% | 4.34% |
| AQR Capital Management LLC | $643.5M | 3,818,037 | -22.7% | 3.78% |
| Renaissance Technologies LLC | $393.7M | 2,335,897 | -3.4% | 2.31% |
| Geode Capital Management, LLC | $359.6M | 2,138,777 | +0.1% | 2.12% |
| Two Sigma Investments, LP | $349.9M | 2,076,260 | -32.2% | 2.06% |
| Vestal Point Capital, LP | $316.8M | 1,880,000 | +50.4% | 1.86% |
| BNP Paribas Asset Management Holding S.A. | $251.9M | 1,494,259 | +0.0% | 1.48% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in NBIX
20 disclosures of 30 on record · median 31d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Lisa C. McClainSpouseFiled late | Stock | Sale | $1,001 - $15,000 | +23.0%S&P +27.8% · vs S&P 500 -4.8% | Jun 17, 2025 | Aug 13, 2025 | 57d |
| Lisa C. McClainSpouseFiled late | Stock | Purchase | $1,001 - $15,000 | +23.7%S&P +27.0% · vs S&P 500 -3.3% | Jun 11, 2025 | Aug 13, 2025 | 63d |
| Michael T. McCaul | Stock | Sale | $15,001 - $50,000 | +28.9%S&P +29.4% · vs S&P 500 -0.4% | Nov 19, 2024 | Dec 16, 2024 | 27d |
| Michael T. McCaul | Stock | Sale | $1,001 - $15,000 | +0.9%S&P +36.2% · vs S&P 500 -35.3% | Aug 26, 2024 | Sep 16, 2024 | 21d |
| Michael T. McCaul | Stock | Sale | $15,001 - $50,000 | +44.8%S&P +86.1% · vs S&P 500 -41.2% | Oct 27, 2023 | Nov 13, 2023 | 17d |
| Michael T. McCaul | Stock | Sale | $50,001 - $100,000 | +44.8%S&P +86.1% · vs S&P 500 -41.2% | Oct 27, 2023 | Nov 13, 2023 | 17d |
| Michael T. McCaul | Stock | Purchase | $50,001 - $100,000 | +45.5%S&P +70.5% · vs S&P 500 -25.0% | Aug 14, 2023 | Sep 14, 2023 | 31d |
| Michael T. McCaul | Stock | Purchase | $15,001 - $50,000 | +45.5%S&P +70.5% · vs S&P 500 -25.0% | Aug 14, 2023 | Sep 14, 2023 | 31d |
| Michael T. McCaulFiled late | Stock | Sale | $15,001 - $50,000 | +48.5%S&P +86.0% · vs S&P 500 -37.5% | May 2, 2023 | Jun 22, 2023 | 51d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +50.3%S&P +87.7% · vs S&P 500 -37.4% | Feb 10, 2023 | Mar 3, 2023 | 21d |
| Michael T. McCaul | Stock | Sale | $1,001 - $15,000 | +31.1%S&P +98.4% · vs S&P 500 -67.3% | Dec 16, 2022 | Jan 19, 2023 | 34d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +29.1%S&P +94.5% · vs S&P 500 -65.4% | Dec 6, 2022 | Jan 6, 2023 | 31d |
| Michael T. McCaul | Stock | Sale | $1,001 - $15,000 | +100.2%S&P +72.8% · vs S&P 500 +27.4% | Jan 28, 2022 | Feb 23, 2022 | 26d |
| Michael T. McCaul | Stock | Sale | $1,001 - $15,000 | +85.7%S&P +64.8% · vs S&P 500 +21.0% | Dec 14, 2021 | Jan 27, 2022 | 44d |
| Michael T. McCaul | Stock | Sale | $15,001 - $50,000 | +81.4%S&P +64.9% · vs S&P 500 +16.5% | Dec 21, 2021 | Jan 27, 2022 | 37d |
| Michael T. McCaul | Stock | Purchase | $15,001 - $50,000 | +52.7%S&P +79.1% · vs S&P 500 -26.3% | Jun 24, 2021 | Jul 16, 2021 | 22d |
| Michael T. McCaul | Stock | Purchase | $15,001 - $50,000 | +68.8%S&P +97.3% · vs S&P 500 -28.5% | Mar 9, 2021 | Apr 19, 2021 | 41d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +54.7%S&P +106.4% · vs S&P 500 -51.7% | Dec 21, 2020 | Jan 11, 2021 | 21d |
| Michael T. McCaulFiled late | Stock | Purchase | $50,001 - $100,000 | +69.8%S&P +116.3% · vs S&P 500 -46.4% | Nov 12, 2020 | Jan 7, 2021 | 56d |
| Michael T. McCaulFiled late | Stock | Sale | $50,001 - $100,000 | +57.6%S&P +126.7% · vs S&P 500 -69.1% | Oct 1, 2020 | Nov 30, 2020 | 60d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Questions
Which members of Congress have traded NBIX?
Lisa C. McClain, Michael T. McCaul, Ro Khanna, Gilbert Ray Cisneros, Jr. disclosed NBIX transactions in the filings shown here.
How quickly are NBIX trades disclosed?
Congressional disclosures took a median of 31 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.